Top Story
- Real World Data
Final results are in from the EVIdeNCE study, which analyzed 309 chronic lymphocytic leukemia (CLL) patients in Italy treated with ibrutinib (Imbruvica; AbbVie/Pharmacyclics), reaffirming the efficacy and safety previously shown in clinical trials. Despite a significant number of patients with cardiovascular comorbidities, these conditions did not [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
ImmunityBio ABIO earnings announcement
ARCA biopharma revealed their most recent quarterly earnings data for Q1. EPS was reported to be -$0.14.
The market liked what it heard. ARCA biopharma rocketed up $0.10 (+2.87%) to $3.58 on light volume [...]
Read MoreProKidney PTCT earnings announcement
PTC Therapeutics exceeded their revenue estimate and fell in line with their EPS estimate, according to their recent quarterly earnings data. Revenue was $210.12M, exceeding estimates by 23.8%.
Not surprisingly, the [...]
Read MoreProcessa Pharmaceuticals BCDA date announcement
BioCardia has an announcement scheduled for December 31, 2024 regarding their recent Phase 3 trial of CardiAMP (BCDA-02). The community is currently bullish on the prospects of progression, as the bulls outnumber bears by five [...]
Read MoreElicio Therapeutics ELTX date announcement
Now that the Phase 1/2 trial of ELI-002 - (AMPLIFY-7P) is completed, Elicio Therapeutics will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 60.9% chance of making it [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest